Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jul;37(4):264–270. doi: 10.1007/BF01518521

Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

J Fagerberg 1, J-E Frödin 1, H Wigzell 2, H Mellstedt 1,✉
PMCID: PMC11038291  PMID: 8348565

Abstract

The antitumor effector functions of unconjugated monoclonal antibodies in cancer therapy are complex. Direct cytotoxic mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytolysis and apoptosis have been suggested. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies as well as T cell (T2 and T3 respectively) responses have also been proposed to be of clinical importance. In this study induction of an immune network cascade in patients with colorectal carcinoma, treated with mAb 17-1A (ab1) was assessed. All patients developed anti-idiotypic antibodies (ab2) of the IgG class after treatment with ab1 and four of nine patients showed induction of mouse Ig reactive T cells [a proliferative response to F(ab′)2 fragments of ab1]. Patients with such a T cell response developed anti-anti-idiotypic antibodies (ab3), while those lacking the T cell reactivity failed to mount an ab3 response. Three of four patients with a T cell response achieved a tumor response to mAb therapy. Thus, all responding patients belonged to the group of individuals developing ab3. Induction of mAb(ab1)-reactive T cells as well as an immune network cascade might be important antitumor effector functions of mAb and should be considered in the future design of mAb-based therapy protocols in cancer patients.

Key words: Monoclonal antibodies, Network response, Anti-idiotype antibodies, T cells, Colon carcinoma

References

  • 1.Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype containing increased numbers of macrophages activated for distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA. 1984;81:3506. doi: 10.1073/pnas.81.11.3506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bergenbrandt S, Österborg A, Holm G, Mellstedt H, Lefvert AK. Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumor load. Br J Haematol. 1991;78:66. doi: 10.1111/j.1365-2141.1991.tb04384.x. [DOI] [PubMed] [Google Scholar]
  • 3.Bruck C, Sung Co M, Slaoui M, Gaulton GN, Smith T, Fields BN, Mullins JI, Greene MI. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparision to the sequence of the external antigen. Proc Natl Acad Sci USA. 1986;83:6578. doi: 10.1073/pnas.83.17.6578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]
  • 5.Cheung NKV, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Stransjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  • 6.van Cleave VH, Naeve CW, Metzger DW. Do antibodies recognize amino acid side chains of protein antigens independently of the carbon backbone? J Exp Med. 1988;167:1841. doi: 10.1084/jem.167.6.1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Barkans JR, Larche M, Ritter MA. Development of anti-idiotypic antibodies against tumor antigens and auto-antigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet. 1988;II:894. doi: 10.1016/s0140-6736(88)92482-8. [DOI] [PubMed] [Google Scholar]
  • 8.Fagreus A, Espmark JÅ, Jonsson J. Mixed haemadsorption: a mixed anti-globulin reaction applied to antigens on a glass surface. Immunology. 1965;9:161. [PMC free article] [PubMed] [Google Scholar]
  • 9.Frödin JE, Pihlstedt P, Lefvert AK, Mellstedt H. Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment. Hybridoma. 1987;6:555. doi: 10.1089/hyb.1987.6.555. [DOI] [PubMed] [Google Scholar]
  • 10.Frödin JE, Harmenberg U, Biberfeld P, Christensson B, Lefvert AK, Rieger Å, Shetye J, Wahren B, Mellstedt H. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinoma. Hybridoma. 1988;7:309. doi: 10.1089/hyb.1988.7.309. [DOI] [PubMed] [Google Scholar]
  • 11.Frödin JE, Faxas ME, Hagström B, Lefvert AK, Masucci G, Nilsson B, Steinitz M, Unger P, Mellstedt H. Induction of anti-idio-typic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome — an important antitumoral effector function? Hybridoma. 1991;10:421. doi: 10.1089/hyb.1991.10.421. [DOI] [PubMed] [Google Scholar]
  • 12.Hearing VJ, Leong SPL, Vieira WD, Law LW. Suppression of established pulmonary metastases by murine melanoma-specific monoclonal antibodies. Int J Cancer. 1991;47:148. doi: 10.1002/ijc.2910470126. [DOI] [PubMed] [Google Scholar]
  • 13.Hellström K, Hellström I. Antitumor vaccines. I. Why cancer vaccines? In: Woodrow GC, Levine MM, editors. New generation vaccines. New York: Marcel-Dekker; 1990. p. 855. [Google Scholar]
  • 14.Herlyn DM, Koprowski H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer. 1981;27:769. doi: 10.1002/ijc.2910270607. [DOI] [PubMed] [Google Scholar]
  • 15.Herlyn DM, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen detection by means of monoclonal antibodies. Proc Natl Acad Sci USA. 1979;76:1438. doi: 10.1073/pnas.76.3.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980;40:717. [PubMed] [Google Scholar]
  • 17.Herlyn DM, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowsky H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma. 1986;5:51. [PubMed] [Google Scholar]
  • 18.Herlyn DM, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA. 1987;84:8055. doi: 10.1073/pnas.84.22.8055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Houghton AN, Mintzner D, Cordon-Cardo C, Welt S, Fliegel F, Vadham S, Carswell E, Melamed MR, Oettgen HF, Old LY. Mouse monoclonal IgG3 antibody detecting 6D3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA. 1986;83:8694. doi: 10.1073/pnas.83.22.8694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Jerne NK. Towards a network theory of the immune system. Ann Immunol. 1974;125:373. [PubMed] [Google Scholar]
  • 22.Kabilan L, Troye-Blomberg M, Perlmann H, Andersson G, Högh B, Petersen E, Björkman A, Perlmann P. T-cell epitopes in Pf155/RESA, a major candidate for aPlasmodium falciparum malaria vaccine. Proc Natl Acad Sci USA. 1988;85:5659. doi: 10.1073/pnas.85.15.5659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA. 1984;81:216. doi: 10.1073/pnas.81.1.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kosmas C, Epenetos AA, Courtenay-Luck NS. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer. 1991;64:492. doi: 10.1038/bjc.1991.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dörken B, Moldenhauer G. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med. 1988;167:345. doi: 10.1084/jem.167.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lehmann HP, Zwicky C, Waibel R, Stahel R. Tumor-antigen-specific humoral immune response of animals to anti-idiotypic antibodies and comparative serological analysis of patients with small-cell lung carcinoma. Int J Cancer. 1992;50:86. doi: 10.1002/ijc.2910500118. [DOI] [PubMed] [Google Scholar]
  • 27.Lindemalm C, Mellstedt H, Biberfeld P, Björkholm M, Christensson B, Holm G, Johansson B, Sundblad R. Blood and lymph node T lymphocyte subsets in non-Hodgkin lymphomas. Scand J Heamatol. 1983;30:68. doi: 10.1111/j.1600-0609.1983.tb00636.x. [DOI] [PubMed] [Google Scholar]
  • 28.LoBuglio AF, Saleh MN, Lee J, Khazaeci MB, Carrano R, Holden H, Wheeler RH. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst. 1988;80:932. doi: 10.1093/jnci/80.12.932. [DOI] [PubMed] [Google Scholar]
  • 29.Mellstedt H, Holm G. In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities. Clin Exp Immunol. 1973;15:309. [PMC free article] [PubMed] [Google Scholar]
  • 30.Mellstedt H, Frödin JE, Biberfeld P, Fagerberg J, Giscombe R, Hernandez A, Masucci G, Li SL, Steinitz M. Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to “the internal image of the antigen” (ab2) Int J Cancer. 1991;48:344. doi: 10.1002/ijc.2910480306. [DOI] [PubMed] [Google Scholar]
  • 31.Mellstedt H, Frödin JE, Masucci G, Ragnhammar P, Fagerberg J, Hjelm AL, Shetye J, Wersäll P, Österborg A. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol. 1991;18:462. [PubMed] [Google Scholar]
  • 32.Neville AM, Gusterson BA. Monoclonal antibodies and human tumours: pathological and clinical aspects. Eur J Cancer Clin Oncol. 1985;21:355. doi: 10.1016/0277-5379(85)90136-1. [DOI] [PubMed] [Google Scholar]
  • 33.Raychaudhuri S, Kang C-Y, Kaveri S-V, Kieber-Emmons T, Köhler H. Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic, and biologic properties of protective and nonprotective Ab2 . J Immunol. 1990;145:760. [PubMed] [Google Scholar]
  • 34.Sears HF, Mattis J, Herlyn D, Hayry P, Atkinson B, Ermst C, Steplewski Z, Koprowski H. Phase I clinical trial of monoclonal antibody treatment of gastrointestinal tumors. Lancet. 1982;I:762. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
  • 35.Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985;45:5910. [PubMed] [Google Scholar]
  • 36.Shaw D, Khazaeli MB, Suu L, Ghrayeb J, Dadonna P, McKinney S, Lobuglio A. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol. 1987;138:4534. [PubMed] [Google Scholar]
  • 37.Steinitz M, Tamir S, Frödin JE, Lefvert AK, Mellstedt H. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol. 1988;141:3516. [PubMed] [Google Scholar]
  • 38.Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine IgG2a anti-tumor immunoglobulins destroy human cancer cells. Science. 1983;221:865. doi: 10.1126/science.6879183. [DOI] [PubMed] [Google Scholar]
  • 39.Steplweski Z, Blaszezyle M, Herlyn D, Herlyn M, Koprowski H. Monoclonal antibodies and breast cancer. Boston: Nijhoff; 1985. Effector cells in ADCC with antibreast cancer monoclonal antibodies; p. 134. [Google Scholar]
  • 40.Sun L, Curtis P, Rabrowicz-Szulezyska E, Ghrayeb J, Morrison S, Chang N, Koprowski H. Chimeric antibodies with 17-1A derived variable and human constant regions. Hybridoma. 1986;5(Suppl 1):17. [PubMed] [Google Scholar]
  • 41.Traub UC, DeJager RL, Primus FJ, Losman M, Goldenberg DM. Anti-idiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1988;48:4002. [PubMed] [Google Scholar]
  • 42.Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science. 1989;245:301. doi: 10.1126/science.2787530. [DOI] [PubMed] [Google Scholar]
  • 43.Waller M, Curry N, Mallory J. Immunochemical and serological studies of enzymatically fractionated human IgG immunoglobulins. I. Hydrolysis with pepsin, papain, ficin and bromelin. Immunochemistry. 1968;5:577. doi: 10.1016/0019-2791(68)90093-1. [DOI] [PubMed] [Google Scholar]
  • 44.Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proc Natl Acad Sci USA. 1989;86:3787. doi: 10.1073/pnas.86.10.3787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicitiy of125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res. 1989;49:2952. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES